Denali Therapeutics (DNLI) Accumulated Depreciation & Amortization (2017 - 2024)
Historic Accumulated Depreciation & Amortization for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to $7.8 million.
- Denali Therapeutics' Accumulated Depreciation & Amortization fell 5336.6% to $7.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.8 million, marking a year-over-year decrease of 5336.6%. This contributed to the annual value of $7.8 million for FY2024, which is 5336.6% down from last year.
- Latest data reveals that Denali Therapeutics reported Accumulated Depreciation & Amortization of $7.8 million as of Q4 2024, which was down 5336.6% from $16.7 million recorded in Q4 2023.
- Denali Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $16.7 million during Q4 2023, with a 5-year trough of $7.8 million in Q4 2024.
- Its 5-year average for Accumulated Depreciation & Amortization is $10.4 million, with a median of $8.6 million in 2021.
- Per our database at Business Quant, Denali Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 6082.69% in 2023 and then crashed by 5336.6% in 2024.
- Denali Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $8.5 million in 2020, then increased by 0.81% to $8.6 million in 2021, then increased by 20.93% to $10.4 million in 2022, then surged by 60.83% to $16.7 million in 2023, then crashed by 53.37% to $7.8 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $7.8 million for Q4 2024, versus $16.7 million for Q4 2023 and $10.4 million for Q4 2022.